Evidence map›Paper›PMID 42112264›Full record

ArticleJournal of exercise rehabilitation2026

Stem cell therapy alleviates hair loss caused by COVID-19 vaccination.

Suyeon Kim

Abstract read
In one paragraph

Article in Journal of exercise rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Suyeon KimGangnam Seran Clinic, Seoul, Korea.ORCID https://orcid.org/0000-0001-9954-6473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A case of a female patient with hair loss induced by coronavirus disease 2019 (COVID-19) vaccination who was treated with autologous CD34+ enriched hematopoietic progenitor cell fraction (CD34+ HPCF) and umbilical cord blood-derived mesenchymal stem cells (UC-MSCs) was reported. The patient presented with generalized pain and hair loss after COVID-19 vaccination. The patient received subcutaneous injections of autologous CD34+ HPCF at 1-cm intervals into the scalp. These injections were administered once a week for a total of 10 times, except in weeks 5 and 10. During this period, UC-MSCs were administered intravenously at dose of 7×10

Indexed as

CD34+ HPCFCOVID-19 vaccinationHair loss treatmentStem cell therapyUC-MSCs

Identifiers

PMID42112264
PMCPMC13153781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.